Newbridge Financial Services Group Inc. acquired a new position in shares of Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 70,000 shares of the company's stock, valued at approximately $401,000. Newbridge Financial Services Group Inc. owned approximately 0.42% of Coya Therapeutics at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its holdings in Coya Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company's stock worth $918,000 after purchasing an additional 4,485 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Coya Therapeutics during the second quarter worth approximately $101,000. Finally, GHP Investment Advisors Inc. acquired a new position in shares of Coya Therapeutics in the 3rd quarter valued at $169,000. Institutional investors and hedge funds own 39.75% of the company's stock.
Coya Therapeutics Stock Performance
COYA traded up $0.23 during trading on Thursday, hitting $6.84. The stock had a trading volume of 39,140 shares, compared to its average volume of 65,726. The firm has a market capitalization of $114.28 million, a P/E ratio of -10.52 and a beta of 0.47. The company's 50-day moving average price is $5.92 and its 200 day moving average price is $6.38. Coya Therapeutics, Inc. has a twelve month low of $4.75 and a twelve month high of $10.69.
Analysts Set New Price Targets
A number of equities analysts have recently commented on COYA shares. Chardan Capital reaffirmed a "buy" rating and issued a $14.00 target price on shares of Coya Therapeutics in a report on Thursday, February 6th. D. Boral Capital reaffirmed a "buy" rating and issued a $15.00 target price on shares of Coya Therapeutics in a report on Thursday, February 6th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $18.00 target price on shares of Coya Therapeutics in a report on Monday, November 11th.
Check Out Our Latest Stock Report on Coya Therapeutics
Coya Therapeutics Profile
(
Free Report)
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Read More
Before you consider Coya Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coya Therapeutics wasn't on the list.
While Coya Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
